MedTrace Logo

Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran

NCT05873868 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-05

No results posted yet for this study

Summary

ATTRv amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms).

Patisiran and vutrisiran have shown protective effects on the progression of neurological damage.

The effects of Patisiran or vutrisiran on the heart remain incompletely understood. The aim of this study is to better understand the morphological and functional cardiac consequences in ATTRv patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran or vutrisiran

Conditions

  • Transthyretin Amyloidosis
  • Amyloidosis, Hereditary

Interventions

OTHER

Six minutes walk test

Six minutes walk test just before first intake of treatment and after 1 and 2 years

OTHER

Kansas City questionnaire

Kansas City questionnaire just before first intake of treatment and after 1 and 2 years

OTHER

COMPASS31 self questionnaire

Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Erwan Donal · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873868 on ClinicalTrials.gov